Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_1
2
50%
Ph phase_3
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

recruiting4100%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188
recruitingphase_3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227
recruitingphase_1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

NCT07358546
recruitingphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

NCT07335198

Clinical Trials (4)

Showing 4 of 4 trials
NCT07221188Phase 3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Recruiting
NCT07221227Phase 3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Recruiting
NCT07358546Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Recruiting
NCT07335198Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4